BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) saw a significant decrease in short interest in September. As of September 29th, there was short interest totalling 10,746,206 shares, a decrease of 25.1% from the September 15th total of 14,348,677 shares. Approximately 11.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 2,214,130 shares, the short-interest ratio is presently 4.9 days.

BCRX has been the subject of several research analyst reports. Piper Jaffray Companies reiterated an “overweight” rating and set a $15.00 price target (up from $13.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, September 5th. Noble Financial reiterated a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 8th. ValuEngine upgraded shares of BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, August 28th. Zacks Investment Research downgraded shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Wednesday, September 6th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $8.78.

Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) opened at 5.19 on Friday. The firm’s market capitalization is $417.42 million. BioCryst Pharmaceuticals has a 12-month low of $3.75 and a 12-month high of $9.25. The company has a 50-day moving average price of $5.22 and a 200-day moving average price of $5.69.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). BioCryst Pharmaceuticals had a negative net margin of 160.97% and a negative return on equity of 276.62%. The firm had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $5.79 million. During the same quarter in the previous year, the firm posted ($0.22) EPS. BioCryst Pharmaceuticals’s revenue was down 35.4% compared to the same quarter last year. Equities analysts predict that BioCryst Pharmaceuticals will post ($0.75) EPS for the current year.

In other news, Director Fred E. Cohen sold 54,250 shares of the company’s stock in a transaction on Monday, September 18th. The shares were sold at an average price of $5.42, for a total transaction of $294,035.00. Following the completion of the transaction, the director now directly owns 173,660 shares in the company, valued at $941,237.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.80% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc increased its position in shares of BioCryst Pharmaceuticals by 4.9% during the second quarter. Legal & General Group Plc now owns 18,346 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 860 shares during the period. Principal Financial Group Inc. increased its position in shares of BioCryst Pharmaceuticals by 0.3% during the first quarter. Principal Financial Group Inc. now owns 13,250 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 45 shares during the period. Fox Run Management L.L.C. purchased a new position in shares of BioCryst Pharmaceuticals during the second quarter valued at about $126,000. Janney Montgomery Scott LLC increased its position in shares of BioCryst Pharmaceuticals by 4.7% during the second quarter. Janney Montgomery Scott LLC now owns 33,335 shares of the biotechnology company’s stock valued at $185,000 after buying an additional 1,500 shares during the period. Finally, Pacad Investment Ltd. purchased a new position in shares of BioCryst Pharmaceuticals during the second quarter valued at about $196,000. Institutional investors own 70.21% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2017/10/13/short-interest-in-biocryst-pharmaceuticals-inc-bcrx-drops-by-25-1.html.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.